Stock Analysis on Net

Boston Scientific Corp. (NYSE:BSX)

This company has been moved to the archive! The financial data has not been updated since May 4, 2023.

Cash Flow Statement

The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Boston Scientific Corp., consolidated cash flow statement

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net income (loss) 698 1,041 (82) 4,700 1,671
(Gain) loss on disposal of businesses and assets 22 (78)
Depreciation and amortization 1,136 1,093 1,123 1,011 894
Deferred and prepaid income taxes (63) (124) (82) (4,301) (87)
Stock-based compensation expense 220 194 170 157 140
Goodwill and other intangible asset impairment charges 132 370 533 105 35
Net (gain) loss on investments and notes receivable 1 (250) (398) 30 (155)
Contingent consideration net expense (benefit) 35 (136) (100) (35) (21)
Inventory step-up amortization 32 34 58 46 6
Debt extinguishment costs 194
Other, net 124 77 244 419 (4)
Trade accounts receivable (220) (279) 335 (130) (110)
Inventories (321) (346) (65) (290) (83)
Other assets (209) (134) (200) 45 (172)
Accounts payable, accrued expenses and other liabilities (255) 408 (28) 79 (1,804)
Increase (decrease) in operating assets and liabilities, excluding purchase accounting (1,005) (351) 42 (296) (2,169)
Adjustments to reconcile net income (loss) to cash provided by operating activities 828 829 1,590 (2,864) (1,361)
Cash provided by operating activities 1,526 1,870 1,508 1,836 310
Purchases of property, plant and equipment and internal use software (588) (554) (376) (461) (316)
Proceeds from sale of property, plant and equipment 12 14 12 7 14
Payments for acquisitions of businesses, net of cash acquired (1,542) (2,259) (3) (4,382) (1,448)
(Payments for) proceeds from investments and acquisitions of certain technologies (24) 279 (146) (148) (171)
Proceeds from disposal of certain businesses and assets 5 826 15 90
Proceeds from royalty rights 70 82 87 52
(Payments for) proceeds from settlements of hedge contracts 56 15 (199)
Cash used for investing activities (2,011) (1,597) (411) (5,041) (1,921)
Payment of contingent consideration previously established in purchase accounting (336) (15) (49) (66) (19)
Payments for royalty rights (75) (85) (97) (69)
Proceeds from royalty rights transfer 256
Payments on short-term borrowings (250) (2,950) (1,000)
Proceeds from short-term borrowings, net of debt issuance costs 2,245 700 999
Net increase (decrease) in commercial paper (1) (714) (575) 21
Payments on borrowings from credit facilities (1,919) (569)
Proceeds from borrowings on credit facilities 1,916 569
Payments on long-term borrowings and debt extinguishment costs (3,184) (1,260) (3,560) (602)
Proceeds from long-term borrowings, net of debt issuance costs 3,270 1,683 7,229 987
Cash dividends paid on preferred stock (55) (55) (28)
Net proceeds from issuance of preferred stock in connection with public offering 975
Net proceeds from issuance of common stock in connection with public offering 975
Payments for repurchase of common stock (535)
Cash used to net share settle employee equity awards (53) (50) (59) (65) (56)
Proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans 136 110 110 123 102
Cash provided by (used for) financing activities (548) (95) 293 2,973 1,432
Effect of foreign exchange rates on cash (9) (5) (2) 10 (9)
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents (1,042) 173 1,388 (222) (188)
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period 2,168 1,995 607 829 1,017
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period 1,126 2,168 1,995 607 829

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

Cash flow statement item Description The company
Cash provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Boston Scientific Corp. cash provided by operating activities increased from 2020 to 2021 but then slightly decreased from 2021 to 2022 not reaching 2020 level.
Cash used for investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Boston Scientific Corp. cash used for investing activities decreased from 2020 to 2021 and from 2021 to 2022.
Cash provided by (used for) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Boston Scientific Corp. cash provided by (used for) financing activities decreased from 2020 to 2021 and from 2021 to 2022.